Patent ID: 8007796

Claim:
A method for the treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) or B cell leukemia, the method comprising the administration of a pharmaceutical composition comprising a bispecific single chain antibody construct to a subject in the need thereof, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (V H ) and the corresponding variable light chain regions (V L ) regions are arranged, from N-terminus to C-terminus, in the order, V L (CD19)-V H (CD19)-V H (CD3)-V L (CD3), V H (CD19)-V L (CD19)-V H (CD3)-V L (CD3), V H (CD3)-V L (CD3)-V H (CD19)-V L (CD19) or V H (CD3)-V L (CD3)-V L (CD19)-V H (CD19), wherein the bispecific single chain antibody construct is administered for at least 1 week in a daily dose of 10 μg to 80 μg per square meter patient body surface area and wherein the daily dose is administered over at least 6 h, and wherein each VL and VH region comprises a CDR1, CDR2, and CDR3 region.